Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Prognostic Value Of Lymph Node Features In Patients Diagnosed With Stage Iiic Endometrial Adenocancer.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Prognostic Value Of Lymph Node Features In Patients Diagnosed With Stage Iiic Endometrial Adenocancer.

Related Experiment Video

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

11.4K

Prognostic value of lymph node features in patients diagnosed with stage IIIC endometrial adenocancer.

Varol Gülseren1, İlker Çakır2, İsa Aykut Özdemir3

  • 1Department of Obstetrics and Gynecology, Faculty of Medicine, Division of Gynecologic Oncology, Erciyes University, Kayseri, Turkey.

Journal of Cancer Research and Therapeutics
|February 20, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Large lymph node metastasis in endometrial adenocancer (EAC) significantly impacts patient survival. This finding highlights the importance of metastatic lymph node size in predicting outcomes for EAC patients with lymph node involvement.

More Related Videos

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.1K
Quantification of Tumor Cell Adhesion in Lymph Node Cryosections
06:09

Quantification of Tumor Cell Adhesion in Lymph Node Cryosections

Published on: February 9, 2020

12.0K

Related Experiment Videos

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

11.4K
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.1K
Quantification of Tumor Cell Adhesion in Lymph Node Cryosections
06:09

Quantification of Tumor Cell Adhesion in Lymph Node Cryosections

Published on: February 9, 2020

12.0K

Area of Science:

  • Gynecologic Oncology
  • Pathology
  • Cancer Research

Background:

  • Endometrial adenocancer (EAC) is a common gynecologic malignancy.
  • Lymph node (LN) involvement is a critical prognostic factor in EAC staging and treatment.
  • Identifying specific LN features that influence survival is crucial for personalized treatment strategies.

Purpose of the Study:

  • To investigate the lymph node (LN) features that most significantly affect survival in endometrial adenocancer (EAC) patients with confirmed LN involvement.
  • To determine the prognostic value of LN size, number, and location in stage IIIC EAC.

Main Methods:

  • Retrospective analysis of 120 stage IIIC endometrioid-type EAC patients.
  • Patients underwent hysterectomy and systematic retroperitoneal lymphadenectomy.
  • LN metastasis evaluated based on size (<10 mm vs. ≥10 mm), number (single vs. multiple), and location (pelvic vs. paraaortic).
  • Cox regression analysis used to assess impact on disease-free survival (DFS) and overall survival (OS).

    • Main Results:

    • Large-sized metastatic lymph nodes (≥10 mm) were identified as an independent prognostic factor for both DFS (HR=5.4, P=0.035) and OS (HR=9.0, P=0.033).
    • The number of metastatic LNs did not significantly impact DFS or OS (P > 0.09).
    • The location of metastatic LNs (pelvic vs. paraaortic) was not an independent prognostic factor for DFS or OS (P > 0.12).

    Conclusions:

    • Large metastatic lymph node size is a significant independent predictor of poorer survival in stage IIIC endometrial adenocancer.
    • LN size, rather than number or location, is the key feature influencing prognosis in this patient cohort.
    • Further large-scale prospective studies are warranted to validate these findings and refine prognostic models for EAC.